TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35640004

Group type: EXPERIMENTAL
Intervention: Automatic BM segmentation using multilabel nnU-Net algorithm
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Radiomics analysis of 30 different BM spaces (BMS)
Number of subjects: 102
Study: 35640019

Group type: EXPERIMENTAL
Intervention: Ultra-high-resolution CCTA with Bv40 kernel, slice thickness of 0.6 mm
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ultra-high-resolution CCTA with Bv89 kernel, slice thickness of 0.2 mm
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bv64 and Bv72 kernels for delineation of coronary artery plaques
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ultra-high-resolution CCTA with PCD-CT
Number of subjects: 20
Study: 35640058

Group type: EXPERIMENTAL
Intervention: iKinnect app
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 35640224

Group type: EXPERIMENTAL
Intervention: Avapritinib
Number of subjects: 31
Study: 35640276

Group type: EXPERIMENTAL
Intervention: UGN-102 (mitomycin-containing reverse thermal gel), 6 weekly instillations
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: UGN-102 (mitomycin-containing reverse thermal gel)
Number of subjects: 63
Study: 35640431

Group type: EXPERIMENTAL
Intervention: Fenfluramine (0.2 mg/kg/day, titrated to a maximum of 0.7 mg/kg/day or 0.4 mg/kg/day with stiripentol)
Number of subjects: 327
Study: 35640474

Group type: EXPERIMENTAL
Intervention: NLG207 12 mg/m2 in combination with enzalutamide
Number of subjects: 4
Study: 35640561

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for >1 year
Number of subjects: 215

Group type: COMPARATOR
Intervention: No lifestyle intervention
Number of subjects: 215
Study: 35640864

Group type: EXPERIMENTAL
Intervention: Community-based pelvic floor physical therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Squeeze pressure (>192.5 mm Hg on at least 1 of 3 attempts)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Limited squeeze duration (inability to sustain 50% of squeeze pressure for >20 seconds)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of BET with squeeze duration (BET > 6.5 seconds and limited squeeze duration)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: BET as a single test
Number of subjects: 60
Study: 35640959

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FVC <70% predicted
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Major (>10%) improvement/worsening in FVC
Number of subjects: 0
Study: 35640975

Group type: EXPERIMENTAL
Intervention: Hippocampal avoidance prophylactic cranial irradiation (HA-PCI)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Conventional prophylactic cranial irradiation (PCI)
Number of subjects: 103
Study: 35641193

Group type: EXPERIMENTAL
Intervention: Resilience
Number of subjects: 17840

Group type: EXPERIMENTAL
Intervention: Greater overall diet quality
Number of subjects: 17840

Group type: EXPERIMENTAL
Intervention: Emotional eating
Number of subjects: 17840
Study: 35641194

Group type: EXPERIMENTAL
Intervention: 10 mg of phylloquinone thrice weekly
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 35641481

Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg (day 1), Apatinib 250 mg daily, Eribulin 1.4 mg/m²
Number of subjects: 46
Study: 35641780

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg) with milvexian (30 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Diltiazem (240 mg) with milvexian (30 mg)
Number of subjects: 28
Study: 35641830

Group type: EXPERIMENTAL
Intervention: Removable percutaneous interspinous process spacer (IPS) (LobsterProject® Techlamed®)
Number of subjects: 59
Study: 35641923

Group type: EXPERIMENTAL
Intervention: Stand and Move at Work intervention
Number of subjects: 12
Study: 35641962

Group type: EXPERIMENTAL
Intervention: IgG1 deficiency
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: IgG2 deficiency
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: IgG3 deficiency
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: IgG4 deficiency
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Two or more IgG subclass deficiencies
Number of subjects: 489
Study: 35642431

Group type: EXPERIMENTAL
Intervention: ABBV-011 (calicheamicin-based antibody-drug conjugate)
Number of subjects: 0
Study: 35642432

Group type: EXPERIMENTAL
Intervention: H3B-6545, a covalent ERα antagonist
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fulvestrant (standard-of-care)
Number of subjects: 0
Study: 35642907

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 0
Study: 35643089

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (300 mg orally once a day from the 24th week of gestation until 6 weeks postpartum)
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate for more than 4 weeks before giving birth
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate for less than 4 weeks before giving birth
Number of subjects: 1194

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate ineligible group
Number of subjects: 1194

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate ineligible group without HBIg
Number of subjects: 1194
Study: 35643306

Group type: COMPARATOR
Intervention: TRAIL levels in COVID-19 patients
Number of subjects: 132

Group type: COMPARATOR
Intervention: IP-10 levels in COVID-19 patients
Number of subjects: 132

Group type: COMPARATOR
Intervention: CRP levels in COVID-19 patients
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Obesity as a predictor of in-ICU mortality
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: CRP as a predictor of in-ICU mortality
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Peak IP-10 as a predictor of in-ICU mortality
Number of subjects: 132
Study: 35643387

Group type: EXPERIMENTAL
Intervention: Rod intercept time (RIT)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Cone decay, cone plateau, time to rod-cone break, rod adaptation rate (S2), area under the curve
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Cone plateau
Number of subjects: 191
Study: 35643571

Group type: COMPARATOR
Intervention: Mean 24-h systolic BP in T2D (128.8±11.7 mmHg)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Concentric LV remodeling in T2D (mass/volume 0.91±0.15 g/mL)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Decreased myocardial perfusion reserve in T2D (2.82±0.83)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Systolic dysfunction in T2D (global longitudinal strain 16.0±2.3%)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Diastolic dysfunction in T2D (E/e' 9.30±2.43)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Mean 24-h systolic BP
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Mean 24-h diastolic BP
Number of subjects: 205
Study: 35643589

Group type: EXPERIMENTAL
Intervention: BEMPEG 0.006 mg/kg plus nivolumab 360 mg intravenously every 3 weeks
Number of subjects: 41
Study: 35643624

Group type: EXPERIMENTAL
Intervention: Palbociclib plus an aromatase inhibitor (PAL+AI) initiated at 125 mg/d
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Palbociclib plus an aromatase inhibitor (PAL+AI) initiated at 75/100 mg/d
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Palbociclib plus an aromatase inhibitor (PAL+AI)
Number of subjects: 813
Study: 35643966

Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 76
Study: 35643967

Group type: EXPERIMENTAL
Intervention: 10-µg bimatoprost implant
Number of subjects: 395

Group type: COMPARATOR
Intervention: Topical timolol maleate 0.5%
Number of subjects: 395
Study: 35644866

Group type: EXPERIMENTAL
Intervention: Participants with diabetes in the iNPHORM study
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Risk factors identified in the final model
Number of subjects: 1206
Study: 35646453

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study: 35646641

Group type: EXPERIMENTAL
Intervention: Intrathecal prophylaxis with methotrexate
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate-based treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: PTCL without initial CNS disease
Number of subjects: 29

Group type: COMPARATOR
Intervention: PTCL with initial CNS and systemic disease
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: CNS relapse
Number of subjects: 29
Study: 35646767

Group type: EXPERIMENTAL
Intervention: Baropodometric assessment before and after a 5-month clinical training session
Number of subjects: 194
Study: 35647043

Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 35647050

Group type: EXPERIMENTAL
Intervention: Moxibustion over lung meridian (LU5)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Moxibustion over heart meridian (HT3)
Number of subjects: 80
Study: 35647062

Group type: EXPERIMENTAL
Intervention: Simultaneous Multi-Point Pacing (3P-MPP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential Multi-Point Pacing
Number of subjects: 0
Study: 35647063

Group type: EXPERIMENTAL
Intervention: Mid-RSS <50%
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: Epi-RSS <50%
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: Intramyocardial-RSS <50%
Number of subjects: 1506
Study: 35647078

Group type: EXPERIMENTAL
Intervention: LSTM_INR model
Number of subjects: 782

Group type: COMPARATOR
Intervention: MAPB_INR model
Number of subjects: 782
Study: 35647344

Group type: EXPERIMENTAL
Intervention: Composite blocks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Ceramic blocks
Number of subjects: 54
Study: 35647711

Group type: EXPERIMENTAL
Intervention: Danuglipron (PF-06882961), an orally bioavailable small-molecule GLP-1R agonist, administered orally.
Number of subjects: 0
Study: 35647759

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35647908

Group type: EXPERIMENTAL
Intervention: sintilimab 200 mg every 3 weeks (21 patients), 1 mg/kg every 2 weeks (2 patients), 3 mg/kg every 2 weeks (1 patient)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: sintilimab
Number of subjects: 24
Study: 35647938

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: G/nab-P
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Effective regimen as predicted by the chemosensitivity assay
Number of subjects: 70

Group type: COMPARATOR
Intervention: Entire study cohort
Number of subjects: 70
Study: 35648149

Group type: EXPERIMENTAL
Intervention: 4β-hydroxycholesterol (4βOHC) concentrations
Number of subjects: 96
Study: 35648151

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 2814

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 2814

Group type: EXPERIMENTAL
Intervention: Tofacitinib (5 or 10 mg BID)
Number of subjects: 2814

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 2814
Study: 35648213

Group type: EXPERIMENTAL
Intervention: External Ventricular Device (EVD)
Number of subjects: 878

Group type: COMPARATOR
Intervention: Intraparencymal monitor (IP)
Number of subjects: 878
Study: 35648298

Group type: EXPERIMENTAL
Intervention: Weight loss treatment
Number of subjects: 46

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 46
Study: 35648329

Group type: EXPERIMENTAL
Intervention: Urine flow monitoring during cardiac surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 35648463

Group type: EXPERIMENTAL
Intervention: 18-week core and pelvic health rehabilitation program starting 6 weeks postpartum and a 12-week resistance and high-intensity interval training program starting 12 weeks postpartum.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care with no prescribed intervention.
Number of subjects: 0
Study: 35648811

Group type: EXPERIMENTAL
Intervention: Efdamrofusp alfa (IBI302)
Number of subjects: 0
Study: 35649117

Group type: EXPERIMENTAL
Intervention: LINAC-Based STAR
Number of subjects: 0
Study: 35649178

Group type: EXPERIMENTAL
Intervention: Allergen Immunotherapy
Number of subjects: 0
Study: 35649202

Group type: EXPERIMENTAL
Intervention: Caregivers' feeding practices, specific practices not detailed, duration not specified.
Number of subjects: 0
Study: 35649212

Group type: EXPERIMENTAL
Intervention: PER-HER
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study: 35649282

Group type: EXPERIMENTAL
Intervention: Total PUFA intake
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: n-3 PUFA intake
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: n-6 PUFA intake
Number of subjects: 109
Study: 35649429

Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD)
Number of subjects: 124
Study: 35649479

Group type: EXPERIMENTAL
Intervention: Laparoscopic ultraradical lymph node debulking using Yasargil clamps
Number of subjects: 43
Study: 35649600

Group type: EXPERIMENTAL
Intervention: HPV vaccination
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: HPV vaccinated women
Number of subjects: 940
Study: 35650179

Group type: EXPERIMENTAL
Intervention: RESTORE (Recovering from Extreme Stressors Through Online Resources and E-health)
Number of subjects: 21
Study: 35650616

Group type: EXPERIMENTAL
Intervention: Higher cumulative fluid balance (median 1.98 L)
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Intermediate cumulative fluid balance (median 0.78 L)
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Lower cumulative fluid balance (median -0.35 L)
Number of subjects: 650
Study: 35650617

Group type: EXPERIMENTAL
Intervention: Physical activity on prescription (PAP) intervention
Number of subjects: 60
Study: 35651319

Group type: EXPERIMENTAL
Intervention: Camera-based method for measuring vital signs (heart rate, blood oxygen saturation, respiratory rate, blood pressure)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Standard reference methods for measuring vital signs
Number of subjects: 214
Study: 35651347

Group type: EXPERIMENTAL
Intervention: STAT-ON sensor
Number of subjects: 84
Study: 35651537

Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 109
Study: 35651624

Group type: EXPERIMENTAL
Intervention: ThyTreg obtained from pediatric thymus using a novel GMP protocol after a short-term culture of 7 days
Number of subjects: 0
Study: 35651649

Group type: EXPERIMENTAL
Intervention: Coagulation parameters in IBD patients
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Acquired and inherited risk factors for thromboembolic events (TE)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Clinical relevance of measuring coagulation parameters
Number of subjects: 149
Study: 35651792

Group type: EXPERIMENTAL
Intervention: BCMA CAR-T cell therapy
Number of subjects: 1

Group type: COMPARATOR
Intervention: Previous treatments (bortezomib, Adriamycin, dexamethasone, lenalidomide, daratumumab)
Number of subjects: 1
Study: 35651818

Group type: EXPERIMENTAL
Intervention: Different sequenced pharmacotherapy options
Number of subjects: 0

Group type: COMPARATOR
Intervention: SSRIs (first-line pharmacotherapy)
Number of subjects: 0
Study: 35651903

Group type: EXPERIMENTAL
Intervention: Implantable cardiac monitor (ICM)
Number of subjects: 100
Study: 35652112

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 40 mg during the first CPR cycle and hydrocortisone 240 mg daily for 7 days maximum (steroids group)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Normal saline-placebo during the first CPR cycle and saline-placebo for postresuscitation shock (control group)
Number of subjects: 184
Study: 35652190

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention to reduce delay from referral to admission, aiming for a benchmark period of 7 days.
Number of subjects: 0
Study: 35652353

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography imaging of the culprit lesion
Number of subjects: 1368
Study: 35652524

Group type: EXPERIMENTAL
Intervention: Resting heart rate
Number of subjects: 0
Study: 35652820

Group type: EXPERIMENTAL
Intervention: Fermented dairy intake (highest tertile)
Number of subjects: 2603

Group type: EXPERIMENTAL
Intervention: Nonfermented dairy intake (each 100-g increase)
Number of subjects: 2603

Group type: EXPERIMENTAL
Intervention: Fermented dairy intake (after excluding cheese intake)
Number of subjects: 2603

Group type: EXPERIMENTAL
Intervention: Fermented dairy intake (after excluding those with elevated depressive symptoms at baseline)
Number of subjects: 2603

Group type: EXPERIMENTAL
Intervention: Nonfermented dairy intake (highest tertile)
Number of subjects: 2603
Study: 35652946

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL)
Number of subjects: 646
Study: 35652960

Group type: EXPERIMENTAL
Intervention: TEM-ESD
Number of subjects: 145
Study: 35653029

Group type: EXPERIMENTAL
Intervention: OC-01 VNS (0.06 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 18
Study: 35653046

Group type: EXPERIMENTAL
Intervention: PrEP initiation following home-based HIV testing
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Home-based HIV testing and referral for PrEP
Number of subjects: 37
Study: 35653116

Group type: EXPERIMENTAL
Intervention: Adjuvant nivolumab
Number of subjects: 39
Study: 35653122

Group type: EXPERIMENTAL
Intervention: SHR-1701 at 30 mg/kg every 3 weeks
Number of subjects: 32
Study: 35653138

Group type: EXPERIMENTAL
Intervention: HPV vaccination as an adjuvant treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: HPV vaccination
Number of subjects: 50
Study: 35653175

Group type: EXPERIMENTAL
Intervention: Recovery Record app delivered on iPhones and Apple Watches, collecting continuous passive measures of physiological activation (heart rate) and physical activity (step count) over 30 days.
Number of subjects: 1019
Study: 35653255

Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheter monitoring in cardiogenic shock
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Myocardial deformation imaging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Echocardiographic and extra-cardiac flow evaluation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various types of pulmonary artery catheters
Number of subjects: 0
Study: 35653380

Group type: EXPERIMENTAL
Intervention: ETCO2 measurement; optimal cutoff value of 25.5 mmHg; sensitivity and specificity both 1.0 (AUC 1.0, p < 0.001) for predicting NGT tracheal misplacement.
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: pH measurement; optimal cutoff value of 4.25; mild diagnostic accuracy (AUC 0.79, p < 0.001) for predicting NGT correct gastric placement.
Number of subjects: 85
Study: 35653431

Group type: EXPERIMENTAL
Intervention: Children with EA
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 21
Study: 35653438

Group type: EXPERIMENTAL
Intervention: Omicron BA.1 breakthrough infection
Number of subjects: 0
Study: 35653440

Group type: EXPERIMENTAL
Intervention: Burst Suppression Ratio (BSR)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Visual burst suppression detection in raw EEG
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intraoperative state entropy values >80
Number of subjects: 90
Study: 35653552

Group type: EXPERIMENTAL
Intervention: 5 μg monovalent HepB vaccine
Number of subjects: 205
Study: 35653756

Group type: EXPERIMENTAL
Intervention: Anorexia Nervosa (AN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary restraint, negative affect, and eating affect regulation expectancies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Persistently low BMI
Number of subjects: 0
Study: 35654563

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35654647

Group type: EXPERIMENTAL
Intervention: Icatibant
Number of subjects: 42
Study: 35654732

Group type: EXPERIMENTAL
Intervention: Epitinib 120 mg QD
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Epitinib 160 mg QD
Number of subjects: 72
Study: 35655180

Group type: EXPERIMENTAL
Intervention: Soft robotic exosuit-augmented high intensity gait training
Number of subjects: 5
Study: 35655302

Group type: EXPERIMENTAL
Intervention: Referral information
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Quality of Referral information-Mental Health scale (cut-off value of 7)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Referral letter quality
Number of subjects: 264
Study: 35655320

Group type: EXPERIMENTAL
Intervention: FGF401 (120 mg qd)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: FGF401 plus spartalizumab (FGF401 120 mg qd and spartalizumab 300 mg Q3W)
Number of subjects: 74

Group type: COMPARATOR
Intervention: FGF401 (50 to 150 mg)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: FGF401
Number of subjects: 74
Study: 35655616

Group type: EXPERIMENTAL
Intervention: Stent placement
Number of subjects: 292
Study: 35655837

Group type: EXPERIMENTAL
Intervention: Infrapopliteal intervention in patients with type III pedal arch
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Infrapopliteal intervention in patients with type I pedal arch
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Infrapopliteal intervention in patients with type II pedal arch
Number of subjects: 26
Study: 35656394

Group type: EXPERIMENTAL
Intervention: Beta-blocker treatment
Number of subjects: 78480

Group type: COMPARATOR
Intervention: No beta-blocker treatment
Number of subjects: 78480
Study: 35656720

Group type: EXPERIMENTAL
Intervention: Triple therapy (TT: 1 anticoagulant and 2 antiplatelet agents)
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Dual therapy (1 anticoagulant + 1 antiplatelet agent)
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Triple therapy (TT)
Number of subjects: 514
Study: 35656931

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist
Number of subjects: 6067

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants
Number of subjects: 6067

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants for treating AF
Number of subjects: 6067
Study: 35656973

Group type: EXPERIMENTAL
Intervention: Multidomain physical rehabilitation intervention
Number of subjects: 0